ClinConnect ClinConnect Logo
Search / Trial NCT05730595

Fluorescence Laparoscopic Navigation for Rectal Cancer and Sigmoid Colon Cancer

Launched by CANCER INSTITUTE AND HOSPITAL, CHINESE ACADEMY OF MEDICAL SCIENCES · Feb 7, 2023

Trial Information

Current as of July 09, 2025

Not yet recruiting

Keywords

Colorectal Cancer Fluorescence Laparoscopic Navigation Lymph Node Dissection

ClinConnect Summary

This clinical trial is looking at a new surgical technique called fluorescence laparoscopic navigation to help doctors remove lymph nodes in patients with colorectal cancer. The goal is to see how well this technique works compared to a standard method. It aims to understand both the short-term and long-term results of this surgery, specifically focusing on patients with rectal and sigmoid colon cancer.

To participate in this trial, you need to be between 18 and 75 years old and have a confirmed diagnosis of colorectal cancer. The tumor should be in a suitable location, and you should not have had any serious complications before surgery. If you're interested in joining, it's important to note that the trial is not yet recruiting participants, so you will need to wait until it starts. If you qualify, you can expect to receive specialized care during your surgery, and the results will help improve future treatments for others with similar conditions.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Participants are aged 18-75;
  • Colonoscopy biopsy confirms colorectal adenocarcinoma;
  • Colonoscopy shows that the lower edge of the tumor is located more than 10 cm from the margin or the tumor is located in the upper rectum and sigmoid colon by imaging diagnosis;
  • The tumor is staged cT1-4aNxM0 by preoperative imaging;
  • Participants have no local complications before surgery.
  • Exclusion Criteria:
  • Previous history of malignant colorectal tumor;
  • Multiple primary colorectal tumors;
  • Preoperative imaging reveals suspicious positive lymph nodes in the submesenteric artery root region (area 253);
  • Patients undergoing neoadjuvant therapy before surgery;
  • With contraindications to laparoscopic surgery;
  • Histoty of multiple abdominal and pelvic surgery or extensive abdominal adhesions;
  • Other malignancies were diagnosed within the past 5 years;
  • History of severe mental illness;
  • Pregnant or lactating women;
  • With uncontrolled infection before surgery.

About Cancer Institute And Hospital, Chinese Academy Of Medical Sciences

The Cancer Institute and Hospital of the Chinese Academy of Medical Sciences is a leading research and treatment center dedicated to advancing cancer care through innovative clinical trials and comprehensive patient services. As a prominent institution in oncology, it focuses on integrating cutting-edge research with clinical practice, fostering collaborations that enhance the understanding and treatment of various cancer types. The institute is committed to improving patient outcomes by exploring novel therapies, optimizing treatment protocols, and contributing to the global fight against cancer through rigorous scientific investigation and evidence-based practices.

Locations

Changchun, Jilin, China

Shanghai, Shanghai, China

Shijiazhuang, Hebei, China

Guangzhou, Guangdong, China

Taiyuan, Shanxi, China

Guangzhou, Guangdong, China

Nanjing, Jiangsu, China

Yibin, Sichuan, China

Beijing, Beijing, China

Nanchang, Jiangxi, China

Shenyang, Liaoning, China

Xining, Qinghai, China

Hefei, Anhui, China

Chengdu, Chengdu, China

Fuzhou, Fujian, China

Guangzhou, Guangdong, China

Haerbin, Heilongjiang, China

Binzhou, Shandong, China

Kunming, Yunnan, China

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials